MaxCyte, Inc. Grant of Options (2308A)
September 10 2018 - 1:00AM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 2308A
MaxCyte, Inc.
10 September 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
Maryland, USA - 10 September 2018: MaxCyte (LSE: MXCT, MXCR), a
US-based global company dedicated to driving the acceleration of
the discovery, development, manufacturing and commercialisation of
next-generation, cell-based medicines, announces that on 18 July
2018, a total of 550,300 options of common stock in the Company
("Common Stock") were granted to PDMRs who are directors or
officers of the Company ("Option Grants"). Details of the Option
Grants are given below:
Option Grants to PDMRs
Doerfler, Doug 296,000
--------
Holtz, Ron 134,800
--------
Thompson, J. Stark 23,900
--------
Mandell, Art 23,900
--------
Erck, Stan 23,900
--------
Brooke, Will 23,900
--------
Johnston, John 23,900
--------
Total 550,300
--------
Options Grants to PDMRs vest ratably on a monthly basis over 48
months, have an exercise period of 10 years from date of grant, at
which time they will expire, and have an exercise price equal to
the closing price of MaxCyte's stock on 18 July 2018, of 243
pence.
About MaxCyte
MaxCyte (LSE: MXCT, MXCR) is a US-based global company dedicated
to driving the acceleration of the discovery, development,
manufacturing and commercialization of next-generation, cell-based
medicines. The Company provides its patented, high-performance cell
engineering platform to biopharmaceutical partners engaged in drug
discovery and development, biomanufacturing, and cell therapy,
including gene editing and immuno-oncology. With its robust
delivery platform, MaxCyte's team of scientific experts helps its
partners to unlock their product potential and solve problems. This
platform allows for the engineering of nearly all cell types,
including human primary cells, with any molecule, at any scale. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large-scale, clinical and
commercial grade cell engineering in a non-viral system and with
low-toxicity concerns. The Company's cell-engineering platform is
FDA-accredited, providing MaxCyte's customers and partners with an
established regulatory path to commercialize cell-based medicines.
MaxCyte is also developing CARMA, its proprietary, breakthrough
platform in immuno-oncology, to rapidly manufacture CAR therapies
for a broad range of cancer indications, including solid tumors
where existing CAR-T approaches face
significant challenges. For more information, visit http://www.maxcyte.com/
###
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Emma Earl, Freddy Crossley (Corporate
Finance)
James Stearns (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Lindsey Neville
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Names Doerfler, Doug
Holtz, Ron
Thompson, J. Stark
Mandell, Art
Erck, Stan
Brooke, Will
Johnston, John
--------------------------- ---------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------
a) Position/status Doerfler, Doug - CEO and Director
Holtz, Ron - CFO and Director
Thompson, J. Stark - Non-executive Chairman
Mandell, Art - Non-executive Director
Erck, Stan - Non-executive Director
Brooke, Will - Non-executive Director
Johnston, John - Non-executive Director
--------------------------- ---------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name MaxCyte, Inc.
--------------------------- ---------------------------------------------
b) LEI 54930053YHXULRFCU991
--------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--------------------------------------------------------------------------
a) Description of the Grant of Options over Shares of Common
financial instrument, Stock
type of instrument
--------------------------- ---------------------------------------------
b) Identification code US57777K1060
--------------------------- ---------------------------------------------
c) Nature of the transactions
Grant of Options to PDMRs
--------------------------- ---------------------------------------------
d) Price(s) and volume(s) Doerfler, Doug - 296,000 at an exercise
price of 243pence
Holtz, Ron - 134,800 at an exercise price
of 243 pence
Thompson, J. Stark - 23,900 at an exercise
price of 243 pence
Mandell, Art - 23,900 at an exercise price
of 243 pence
Erck, Stan - 23,900 at an exercise price
of 243 pence
Brooke, Will - 23,900 at an exercise price
of 243 pence
Johnston, John - 23,900 at an exercise
price of 243 pence
--------------------------- ---------------------------------------------
d) Aggregated information n/a
- Aggregated volume
- Price
--------------------------- ---------------------------------------------
e) Date of the transactions 18 July 2018
--------------------------- ---------------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- ---------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEANNNEEAPEFF
(END) Dow Jones Newswires
September 10, 2018 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024